The women’s health and wellness space is booming. The opportunities are real and so are the rewards. This is where you keep up. Welcome to The DXF Edit.
Oura filed to go public this week, banking a $16 billion valuation partly on the years of cycle, pregnancy, and menopause data it holds on its members. In Wisconsin, two Supreme Court justices who used to work for Planned Parenthood will now rule on its lawsuit against the state’s abortion restrictions. And in Massachusetts, a jury spent six days failing to agree on whether Lindsay Clancy’s psychosis excuses killing her three children, a question the internet answered anyway, loudly, before a retrial has even been scheduled.
MONEY MOVES
Oura’s IPO Filing Admits the Real Product Is Your Hormonal History, Not the Ring
Oura filed its S-1 this week, chasing a $16 billion valuation on $1.2 billion in nine-month revenue. Female members now make up 72 percent of the paid base and are growing at a 143 percent annual clip, which is the number every headline will run with. It’s the wrong number.
The filing’s real admission sits deeper in the document. Oura describes its competitive advantage as a “data moat” built from 42 billion hours of physiological data, and names historical data lock-in, not subscription habit, as the thing that keeps members paying. Translation: once your ovulation cycles, pregnancy, and menopause symptoms live inside Oura’s app for three or four years, leaving doesn’t just mean buying a new ring. It means abandoning the only continuous record you have of your own body.
That’s the bet investors are actually pricing at $16 billion, and it’s a smarter one than “women love wearables.”
A subscription you can cancel is a product. A biological archive you can’t take with you is a hostage situation with a monthly fee.
A €15 Million Round Bets Preeclampsia Doesn’t Have to Be a Waiting Game
Spanish startup iPremom raised a €15 million seed round, led by Amadeus Capital Partners with Asabys Partners and APEX Ventures joining, to scale a blood test that catches pregnancy complications months before doctors currently start looking.
For decades, preeclampsia diagnosis has meant a blood pressure cuff and a urine dipstick, both of which only flag trouble once the disease is already underway. iPremom’s platform instead reads a molecular signal in maternal blood as early as 9 to 14 weeks, tied to a failure in how the uterine lining develops, long before a single symptom would show up at a routine appointment. Preeclampsia affects up to 8 percent of pregnancies worldwide, and obstetrics has spent that entire window treating early warning as something optional rather than something owed to every pregnant patient.
The upgrade here isn’t a new symptom to watch for. It’s weeks of warning instead of an emergency room visit, and that’s the difference between managing a known risk and discovering one too late.
RESEARCH & INNOVATION
A Standardized Menopause Score Answers a Real Problem. It Just Hasn’t Been Checked Yet.
Oura is wiring its Menopause Impact Scale, a questionnaire spanning 22 symptoms across seven domains, into ten health platforms including Maven, Tia, Gennev, and Hertility. More than 600,000 members have completed it since May, and the pitch is straightforward: instead of describing hot flashes and brain fog from memory at every new appointment, a woman’s score now travels with her.
The problem it’s targeting is real and well documented. Fewer than one in five primary care physicians receive formal menopause training, and women wait an average of three years to get their symptoms correctly diagnosed as menopause related. A consistent, numeric account of what a woman is actually experiencing is harder to wave off as stress or aging than a single rushed conversation, and for women who have spent years being dismissed, that is not nothing.
It is also not finished. Oura evaluated the instrument on nearly 2,900 participants and submitted the validation manuscript for peer review, a step short of having it independently reviewed and published. Handing an under-trained doctor a confident-looking number does not close the knowledge gap behind the dismissal. It just gives an under-informed decision better packaging. A score can make a woman harder to dismiss. It can also make it easier for a doctor to stop asking questions.
A Startup Wants to Replace Breast Implants With Something Your Body Regrows Instead
Italian medtech Tensive landed up to €20 million in convertible venture debt from the European Investment Bank to bring Regenera, its bioresorbable breast implant, through its final stretch before EU approval, targeted for early 2027. The device is already 94 patients into a clinical trial.
What Regenera is actually built to do goes past the obvious pitch of “softer alternative to silicone.” The scaffold dissolves as a patient’s own tissue regrows in its place, and it’s engineered to stay visibly distinct from surrounding tissue on diagnostic imaging, which means radiologists can target radiotherapy more precisely and track for recurrence without a permanent foreign object clouding the scan. Silicone was never designed with a cancer patient’s follow-up care in mind. This is.
Reconstruction has spent decades being treated as the part that happens after the real medicine is done, a cosmetic decision bolted onto the end of cancer treatment. A material built to help doctors watch for the cancer coming back doesn’t just change what reconstruction looks like. It changes what job reconstruction is doing.
LAW & POLICY
Two Wisconsin Justices Used to Work for Planned Parenthood. Now They’ll Rule on Its Lawsuit.
Planned Parenthood of Wisconsin filed suit this week against the state’s 24-hour abortion waiting period and its rule limiting abortion provision to licensed physicians, arguing both violate the state constitution’s guarantee of personal liberty. The timing wasn’t incidental.
The lawsuit landed days after the Wisconsin Supreme Court seated a newly cemented 5-2 liberal majority, a bench that includes one justice who spent years as a Planned Parenthood lobbyist and another who represented the organization as a private attorney before taking her seat. Wisconsin Right to Life is already calling the suit an attack on informed consent, but that argument is landing in front of a court where two of the five justices carry direct professional history with the plaintiff.
The legal brief still has to be argued and the case still has to be decided on the merits, at least on paper. But it is hard to call the outcome suspenseful when two of the five people ruling on it used to work for the side that just sued. Reproductive law in Wisconsin didn’t change because the legal argument suddenly got stronger. It changed because the people hearing it did.
Flying an Abortion-Pill Banner Over a State Fair Just Became a Bigger Legal Problem Than Prescribing One
For two days over the Kentucky State Fair, a plane towed a banner reading “ABORTION PILLS BY MAIL. Mayday.Health.” above roughly 600,000 fairgoers. Kentucky Attorney General Russell Coleman is now suing Mayday Health, the New York-based nonprofit that chartered it, alleging the group’s website facilitates a felony under the state’s ban on mailing abortion-inducing drugs into Kentucky, on top of violating its consumer protection law.
The gas station ads Coleman investigated back in January were a warning shot. This lawsuit is a different animal: it targets the advertising itself, not the pills, not the prescribing, not even the mailing, just the act of telling Kentuckians the option exists. That’s a far wider net than banning a drug. Once talking about access becomes the violation, the exposure stops belonging to clinics and shield-law doctors and starts belonging to anyone willing to say the words “abortion pills by mail” where someone in a banned state might hear them.
ON THE FEED
Lindsay Clancy’s Case Split the Internet Over a Real Question: Where Does “She Was Sick” Stop Being an Excuse?
A Massachusetts jury spent six days deadlocked 11 to 1 on whether Lindsay Clancy was criminally responsible for killing her three children, and the mistrial that followed settled nothing, in the courtroom or online.
The reaction split along a real fault line, not a chaotic one. Supporters rallying around the case argue that a documented psychiatric emergency, one medicine has treated seriously since the 1980s, deserves the law’s actual compassion rather than a conviction dressed up as justice. Others watching the same trial are asking a harder question: if a mother’s illness can excuse killing her children, what counts as sick enough next time, and who gets to decide. Neither side is arguing in bad faith. They’re disagreeing, sincerely, about where mercy for a mother stops and protection for a child begins.
A retrial doesn’t just face the same unresolved legal question. It has to find twelve people who haven’t already watched the internet decide Clancy’s guilt for them, in comedy sketches, in doxxing campaigns, in six days of a hung jury turned into a live spectacle. The trial made the case impossible to answer cleanly. What happened online may have made it impossible to try again at all.
A Sports Betting Account Is Guessing WNBA Players’ Menstrual Cycles. Their Teams Have More Data and Less Interest.
A sports betting account with close to 30,000 followers tries to infer WNBA players’ cycles from injury-report language like “soreness” and offhand comments, then bets against their performance. Its cycle content pulls up to four million views a video, far more than anything else it posts. The method is unscientific, and the account’s own critics call it exactly that.
But the fact that it exists at all is the story. Female athletes tear their ACLs two to eight times more often than men, largely because estrogen and a hormone called relaxin loosen the ligament during specific cycle phases, a mechanism sports medicine has understood for years. Only six to nine percent of sports science research has ever studied female athletes at all, which is exactly the kind of data gap a team with real resources could close.
A gambler with an Instagram account and no medical training found it worth the effort to guess at this anyway. The teams paying these athletes, with actual medical staff and biometric access, mostly haven’t. Seattle Storm center Ezi Magbegor tore her ACL this week playing for Australia at the FIBA World Cup, and fans immediately pointed to the same unresolved question that’s been sitting there the whole time.